Could a common diabetes drug help fight prostate cancer?
NCT ID NCT07310433
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding dapagliflozin, a diabetes medication, to standard hormone therapy improves outcomes for men with metastatic castrate-resistant prostate cancer. About 60 participants will be randomly assigned to receive either the combination or standard care alone. The study aims to see if the combination delays cancer progression and is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dapagliflozin (a diabetes drug) combined with standard hormone therapy
What this could lead to
If successful, this could point toward a new combination treatment that improves tumor control for men with advanced prostate cancer.
What could go wrong
This is a small, early-phase trial (60 people) and the drug is being repurposed, so results may not be conclusive or generalizable. Side effects from the combination are not yet fully known.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huashan Hospital
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ruijin Hospital
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••